Enlivex therapeutics ltd.ENLV.US Overview

US StockHealthcare

(No presentation for ENLV)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ENLV Overall Performance

ENLV AI Analysis & Strategy

ENLV Recent Performance

-4.35%

Enlivex therapeutics ltd.

0.81%

Avg of Sector

-1.14%

S&P500

ENLV PowerScanner

ENLV Key Information

ENLV Valuation Metrics

ENLV Earnings Table

ENLV Profile

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.